Proactive Investors - Run By Investors For Investors

Anavex Life's Alzheimer's drug awarded orphan status for child seizures

Anavex 2-73 is the company’s lead candidate and currently in a Phase 2a clinical trial for Alzheimer’s disease.
Picture of brain
Infantile spasms usually affect babies

Anavex Life Sciences Corp (Nasdaq:AVXL) has received US orphan drug status in infantile spasms for  a drug it is currently trialing to ease Alzheimer’s.

Anavex 2-73 is the second of the company’s projects to get ODD status, a designation the US Food and Drug Administration awards to fast track treatments for diseases that affect fewer than 200,000 people.

It gives Anavex a seven year window of commercial exclusivity in the US in the area of infantile spasms, prioritized consultation by the FDA on clinical studies and exemptions on some regulatory fees.

An infantile spasm is a specific type of seizure usually in the first year of life and typically between the ages of 4-8 months. Roughly 2-3 babies per 10,000 get them, with peak incidence at 6 months of age and less than 10% of cases presenting after 12 months of age.

Children with symptomatic spasms more frequently exhibit neurological deficits and cognitive and developmental delays, the company said.

Anavex 2-73 is the company’s lead candidate and currently in a Phase 2a clinical trial for Alzheimer’s disease. 

View full AVXL profile View Profile

Anavex Life Sciences Timeline

Related Articles

scientist at petrie dish
May 15 2019
Here we take a closer look at Midatech Pharma PLC (LON:MTPH)
patch
May 20 2019
The New Jersey company's lead product is Twirla, a low-dose prescription contraceptive applied once weekly for three weeks, followed by a week without the patch
skin
April 17 2019
Driving growth was Lojuxta, used to treat a rare and life-threatening disorder that causes abnormally high levels of bad cholesterol. Its sales grew to €13.6mln, up 14.2% year-on-year

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use